期刊文献+

全球重要领域的新药研发与进展 被引量:5

Global Progress of New Drugs in Major Areas
下载PDF
导出
摘要 本文主要聚焦于抗丙肝、调血脂、糖尿病等7大重要治疗领域,通过跟踪这些领域的新药研发进程,对这些领域的药物治疗进展进行了一个较为全面的回顾,并对全球近年来新上市以及在研的治疗药物进行了重点介绍。 This paper mainly focus on anti-HCV, reduced cholesterol, diabetes and several other important therapeutic areas. It reviews the progress of drug therapy in these areas by tracking new drug research and development process, and new drugs listed in recent years and clinical drugs in the research are also introduced.
作者 田月 赵志刚
出处 《药品评价》 CAS 2015年第18期6-11,46,共7页 Drug Evaluation
关键词 重要治疗领域 新药研发 进展 Important Therapeutic Areas Drug Research Progress
  • 相关文献

参考文献17

二级参考文献90

  • 1莫一菲,周健,贾伟平.国际糖尿病联盟2011~2021年全球糖尿病计划解读[J].中国医学前沿杂志(电子版),2012,4(9):20-23. 被引量:16
  • 2周向昭,安国芝,冯冬梅.阿维A治疗斑块状银屑病前后血清肿瘤坏死因子α的检测[J].中华皮肤科杂志,2006,39(3):130-130. 被引量:3
  • 3金晶,叶菲.新型餐后血糖调节剂——格列奈类药物的研究进展[J].国外医学(药学分册),2007,34(1):44-47. 被引量:9
  • 4袁耕.灯盏花素治疗66例银屑病.中华皮肤科杂志,1999,32(2):1351-1351.
  • 5Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China [J]. NEngl JMed, 2010, 362(12): 1090-1101.
  • 6Citeline, Inc. Pipeline. [DB/OL]. [2013-03-12]. http://pipeline.citeline.congCpLogin.aspx.
  • 7Pouwels K B, van Grootheest K. The rosiglitazone decision process at FDA and EMA. What should we learn? [J] IntJRisk SafMed, 2012, 24(2): 73-80.
  • 8Colmers I N, Bowker S L, Majumdar S R, et al. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis [J]. CMAJ, 2012, 184(12): E675-683.
  • 9Bodmer M, Meier C, Kraenzlin M E, et al. Risk of fractures with glitazones: a critical review of the evidence to date [J]. Drug Saf 2009, 32(7): 539-547.
  • 10Riche D M, King S T. Bone loss and fracture risk associated with thiazolidinedione therapy [J]. Pharmacotherapy, 2010, 30(7): 716-727.

共引文献36

同被引文献71

  • 1张新转,朱秀洁,田秀娟,王桂侠.丙型病毒性肝炎并发糖尿病的发病机制及治疗特点[J].中国老年学杂志,2015,35(1):284-285. 被引量:7
  • 2张福奎,贾继东.慢性丙型肝炎合并肝脂肪变的诊治[J].药品评价,2007,4(2):88-90. 被引量:3
  • 3邹栩,顾凯.世界新药研发动向[J].中国新药杂志,2007,16(22):1821-1825. 被引量:5
  • 4Choo Q-L, Kuo G, Weiner AJ, et al.. Isolation of a cDNA clone derivedfrom a blood-borne non-A, non-B viral hepatitis genome[J]. Science, 1989,244: 359-362.
  • 5Lavanchy D. The global burden of hepatitis C[J]. Liver International, 2009,29: 74-81.
  • 6Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosisin chronic hepatitis C virus infection[J]. Hepatology, 2001, 34: 809-816.
  • 7McHutchison JG, Lawitz EJ, Shiffmanm L, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection[J]. New England Journalof Medicine, 2009, 361: 580-593.
  • 8Kiser JJ, Flexner C. Direct-acting antiviral agents for hepatitis C virusinfection[J]. Annual review of pharmacology and toxicology, 2013, 53:427.
  • 9Tang H, Grise H. Cellular and molecular biology of HCV infection andhepatitis[J]. Clinical Science, 2009, 117: 49-65.
  • 10Zeuzem S, Andreone P, Pol S, et al. Telaprevir for Retreatment of HCVInfection[J]. New England Journal of Medicine, 2011, 364: 2417-2428.

引证文献5

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部